DK156725B - Analogifremgangsmaade til fremstilling af 3-(tetrazol-5-yl)-1-azaxantoner - Google Patents
Analogifremgangsmaade til fremstilling af 3-(tetrazol-5-yl)-1-azaxantoner Download PDFInfo
- Publication number
- DK156725B DK156725B DK418678AA DK418678A DK156725B DK 156725 B DK156725 B DK 156725B DK 418678A A DK418678A A DK 418678AA DK 418678 A DK418678 A DK 418678A DK 156725 B DK156725 B DK 156725B
- Authority
- DK
- Denmark
- Prior art keywords
- amino
- oxo
- tetrazol
- benzopyran
- carboxaldehyde
- Prior art date
Links
- -1 TETRAZOL-5-YL Chemical class 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 10
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- RLANGRCXIQESBJ-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical class C=1N=C2C(=O)C3=CC=CC=C3OC2=CC=1C1=NN=NN1 RLANGRCXIQESBJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000003948 formamides Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- TVGIYZVZBKAJRR-UHFFFAOYSA-N 2-amino-4-oxochromene-3-carbaldehyde Chemical compound C1=CC=C2C(=O)C(C=O)=C(N)OC2=C1 TVGIYZVZBKAJRR-UHFFFAOYSA-N 0.000 description 2
- VCBWRHOYURFLHC-UHFFFAOYSA-N 2-amino-8-propan-2-yl-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound NC=1N=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=CC=1C1=NN=NN1 VCBWRHOYURFLHC-UHFFFAOYSA-N 0.000 description 2
- GEQZTCMVWVDEDF-UHFFFAOYSA-N 2-cyanoacetyl chloride Chemical compound ClC(=O)CC#N GEQZTCMVWVDEDF-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FTGRMJKOCZJUCL-UHFFFAOYSA-N CC#N.C1=CC=C2C(=O)C=COC2=C1.C1=CN=C2C(=O)C3=CC=CC=C3OC2=C1 Chemical compound CC#N.C1=CC=C2C(=O)C=COC2=C1.C1=CN=C2C(=O)C3=CC=CC=C3OC2=C1 FTGRMJKOCZJUCL-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- YDPLDMLRERBXAV-UHFFFAOYSA-N aluminum;triazide Chemical compound [Al+3].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] YDPLDMLRERBXAV-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- YAUODDQCNOBEDJ-UHFFFAOYSA-N chromeno[3,2-b]pyridin-10-one Chemical group C1=CN=C2C(=O)C3=CC=CC=C3OC2=C1 YAUODDQCNOBEDJ-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- UBKFNPJMWUJHGB-UHFFFAOYSA-N titanium(4+);tetraazide Chemical compound [Ti+4].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UBKFNPJMWUJHGB-UHFFFAOYSA-N 0.000 description 2
- QFDUTPNKBRXHTC-UHFFFAOYSA-N zinc diazide Chemical compound [Zn++].[N-]=[N+]=[N-].[N-]=[N+]=[N-] QFDUTPNKBRXHTC-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HSAMXAFOGJNFOC-UHFFFAOYSA-N 10-oxo-8-propan-2-ylchromeno[3,2-b]pyridine-3-carbonitrile Chemical compound N#CC1=CN=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=C1 HSAMXAFOGJNFOC-UHFFFAOYSA-N 0.000 description 1
- UNJFLFQKBMSJJR-UHFFFAOYSA-N 2-amino-10-oxo-8-propan-2-ylchromeno[3,2-b]pyridine-3-carbonitrile Chemical compound N#CC1=C(N)N=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=C1 UNJFLFQKBMSJJR-UHFFFAOYSA-N 0.000 description 1
- GCFVPLUXLQEQJX-UHFFFAOYSA-N 2-amino-6-chloro-4-oxochromene-3-carbaldehyde Chemical compound C1=C(Cl)C=C2C(=O)C(C=O)=C(N)OC2=C1 GCFVPLUXLQEQJX-UHFFFAOYSA-N 0.000 description 1
- GBVNVSIAAXOVNQ-UHFFFAOYSA-N 2-amino-6-ethyl-4-oxochromene-3-carbaldehyde Chemical compound O1C(N)=C(C=O)C(=O)C2=CC(CC)=CC=C21 GBVNVSIAAXOVNQ-UHFFFAOYSA-N 0.000 description 1
- FMYYFKHTWRVDSA-UHFFFAOYSA-N 2-amino-6-methoxy-4-oxochromene-3-carbaldehyde Chemical compound O1C(N)=C(C=O)C(=O)C2=CC(OC)=CC=C21 FMYYFKHTWRVDSA-UHFFFAOYSA-N 0.000 description 1
- BSLLMUGLOYSIEZ-UHFFFAOYSA-N 2-amino-8-(dimethylamino)-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound NC=1N=C2C(=O)C3=CC(N(C)C)=CC=C3OC2=CC=1C1=NN=NN1 BSLLMUGLOYSIEZ-UHFFFAOYSA-N 0.000 description 1
- ZTRUJWKCMPGZFS-UHFFFAOYSA-N 2-amino-8-chloro-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound NC1=NC(C(C2=CC(Cl)=CC=C2O2)=O)=C2C=C1C1=NN=NN1 ZTRUJWKCMPGZFS-UHFFFAOYSA-N 0.000 description 1
- PRKUPEGLOFXKFB-UHFFFAOYSA-N 2-amino-8-nitro-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound NC1=NC(C(C2=CC(=CC=C2O2)[N+]([O-])=O)=O)=C2C=C1C1=NN=NN1 PRKUPEGLOFXKFB-UHFFFAOYSA-N 0.000 description 1
- DKAFDKYFEKZRIY-UHFFFAOYSA-N 2-amino-8-propan-2-yl-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.NC=1N=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=CC=1C1=NN=NN1 DKAFDKYFEKZRIY-UHFFFAOYSA-N 0.000 description 1
- CTVRUXBFKXBKSQ-UHFFFAOYSA-N 2-amino-9-hydroxy-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound NC1=NC(C(C2=C(O)C=CC=C2O2)=O)=C2C=C1C1=NN=NN1 CTVRUXBFKXBKSQ-UHFFFAOYSA-N 0.000 description 1
- SDNXHHGFIZGEQK-UHFFFAOYSA-N 2-cyanoacetyl bromide Chemical compound BrC(=O)CC#N SDNXHHGFIZGEQK-UHFFFAOYSA-N 0.000 description 1
- QJNWDOOXIZOGRS-UHFFFAOYSA-N 2-cyanoacetyl fluoride Chemical compound FC(=O)CC#N QJNWDOOXIZOGRS-UHFFFAOYSA-N 0.000 description 1
- GUUUSSQSDWYZOV-UHFFFAOYSA-N 2-cyanoacetyl iodide Chemical compound IC(=O)CC#N GUUUSSQSDWYZOV-UHFFFAOYSA-N 0.000 description 1
- RISKINCQRSLFRK-UHFFFAOYSA-N 2h-chromene-3-carbaldehyde Chemical compound C1=CC=C2OCC(C=O)=CC2=C1 RISKINCQRSLFRK-UHFFFAOYSA-N 0.000 description 1
- NQOLOKKZYCSJRL-UHFFFAOYSA-N 2h-chromene-3-carbonitrile Chemical compound C1=CC=C2OCC(C#N)=CC2=C1 NQOLOKKZYCSJRL-UHFFFAOYSA-N 0.000 description 1
- DEBZQUFVQZPPLC-UHFFFAOYSA-N 2h-chromene-3-carboxylic acid Chemical compound C1=CC=C2OCC(C(=O)O)=CC2=C1 DEBZQUFVQZPPLC-UHFFFAOYSA-N 0.000 description 1
- JNAMVBQCQXZUTA-UHFFFAOYSA-N 2h-pyran-3-carbaldehyde Chemical compound O=CC1=CC=COC1 JNAMVBQCQXZUTA-UHFFFAOYSA-N 0.000 description 1
- SFWNPLLGXKJESA-UHFFFAOYSA-N 4-oxochromene-3-carbonitrile Chemical compound C1=CC=C2C(=O)C(C#N)=COC2=C1 SFWNPLLGXKJESA-UHFFFAOYSA-N 0.000 description 1
- APZYZAXIOWVIFQ-UHFFFAOYSA-N 5-[1-hydroxy-1-(propan-2-ylamino)ethyl]benzene-1,3-diol Chemical compound CC(C)NC(C)(O)C1=CC(O)=CC(O)=C1 APZYZAXIOWVIFQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RNVOVDXHJQAFOS-UHFFFAOYSA-N 8-chloro-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound C=1N=C2C(=O)C3=CC(Cl)=CC=C3OC2=CC=1C1=NN=NN1 RNVOVDXHJQAFOS-UHFFFAOYSA-N 0.000 description 1
- YXFRINHOVVIXGB-UHFFFAOYSA-N 8-ethyl-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound C=1N=C2C(=O)C3=CC(CC)=CC=C3OC2=CC=1C1=NN=NN1 YXFRINHOVVIXGB-UHFFFAOYSA-N 0.000 description 1
- IBCCXBAMNXRXBX-UHFFFAOYSA-N 8-propan-2-yl-3-(2H-tetrazol-5-yl)-1H-chromeno[3,2-b]pyridine-2,10-dione Chemical compound OC=1N=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=CC=1C1=NN=NN1 IBCCXBAMNXRXBX-UHFFFAOYSA-N 0.000 description 1
- WHBROROGJDGSAZ-UHFFFAOYSA-N 8-propan-2-yl-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound C=1N=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=CC=1C1=NN=NN1 WHBROROGJDGSAZ-UHFFFAOYSA-N 0.000 description 1
- QMMWKFPCJSPQES-UHFFFAOYSA-N 8-propan-2-yloxy-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound C=1N=C2C(=O)C3=CC(OC(C)C)=CC=C3OC2=CC=1C1=NN=NN1 QMMWKFPCJSPQES-UHFFFAOYSA-N 0.000 description 1
- YCDFGNHPKLCVOI-UHFFFAOYSA-N 8-tert-butyl-3-(2h-tetrazol-5-yl)chromeno[3,2-b]pyridin-10-one Chemical compound C=1N=C2C(=O)C3=CC(C(C)(C)C)=CC=C3OC2=CC=1C=1N=NNN=1 YCDFGNHPKLCVOI-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZJROUEFTWOKMEF-UHFFFAOYSA-N CN(C=O)C.C(#N)C=1C=NC=2C(C3=CC=CC=C3OC2C1)=O.O=C1C=COC2=C1C=CC=C2 Chemical compound CN(C=O)C.C(#N)C=1C=NC=2C(C3=CC=CC=C3OC2C1)=O.O=C1C=COC2=C1C=CC=C2 ZJROUEFTWOKMEF-UHFFFAOYSA-N 0.000 description 1
- 241001239379 Calophysus macropterus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- UAZDIGCOBKKMPU-UHFFFAOYSA-O azanium;azide Chemical compound [NH4+].[N-]=[N+]=[N-] UAZDIGCOBKKMPU-UHFFFAOYSA-O 0.000 description 1
- UUXFWHMUNNXFHD-UHFFFAOYSA-N barium azide Chemical compound [Ba+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UUXFWHMUNNXFHD-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UETLMBWMVIQIGU-UHFFFAOYSA-N calcium azide Chemical compound [Ca+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UETLMBWMVIQIGU-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VZWWUNGIEIMZOW-UHFFFAOYSA-N chromeno[3,2-b]pyridin-10-one chromen-4-one ethanol Chemical compound CCO.C1=CC=C2C(=O)C=COC2=C1.C1=CN=C2C(=O)C3=CC=CC=C3OC2=C1 VZWWUNGIEIMZOW-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- LNDJVIYUJOJFSO-UHFFFAOYSA-N cyanoacetylene Chemical group C#CC#N LNDJVIYUJOJFSO-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
- TWRAJPCQPHBABR-UHFFFAOYSA-N magnesium;diazide Chemical compound [Mg+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] TWRAJPCQPHBABR-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- DCNUQRBLZWSGAV-UHFFFAOYSA-N n,n-diphenylformamide Chemical compound C=1C=CC=CC=1N(C=O)C1=CC=CC=C1 DCNUQRBLZWSGAV-UHFFFAOYSA-N 0.000 description 1
- FJLHLDBEZKTSOK-UHFFFAOYSA-N n-ethyl-n-methylformamide Chemical compound CCN(C)C=O FJLHLDBEZKTSOK-UHFFFAOYSA-N 0.000 description 1
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- NLFIMXLLXGTDME-UHFFFAOYSA-N propyl 2-cyanoacetate Chemical compound CCCOC(=O)CC#N NLFIMXLLXGTDME-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- PDEROVFZLWBVSG-UHFFFAOYSA-N strontium;diazide Chemical compound [Sr+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] PDEROVFZLWBVSG-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- PCTNAMGLSYHIPL-UHFFFAOYSA-N tin(4+) tetraazide Chemical compound [Sn+4].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] PCTNAMGLSYHIPL-UHFFFAOYSA-N 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Color Printing (AREA)
Description
DK 156725 B
Den foreliggende opfindelse angâr en analogifrem- gangsmâde til fremstilling af hidtil ukendte 3-(tetrazol- 5-yl)-1-azaxantoner med den i indledningen til krav Uvi- 1 2 ste almene formel I, hvor R , R og m har de sammesteds 5 angivne betydninger.
Fremgangsmâden ifolge opfindelsen er ejendommelig ved det i krav l's kendetegnende del angivne.
Farmakologisk har forbindelserne fremragende anti-allergisk og bronkodilaterende virkninger.
10 Fra tysk patentskrift nr. 2521980 kendes der 7- (tetrazol-5-yl)-1-azaxantoner med den almene formel X\s:^O B.
Pif 1 15
13 N J
hvor A betyder nitrogen og B kulstof eller omvendt, og X
betyder hydrogen, halogen eller alkyl.
Det oplyses i skriftet at forbindelserne med formel 7 Π III og salte deraf er værdifulde lægemidler med antialler-gisk virkning.
Ved sammenligning mellem formel I og formel III ses det at en væsentlig strukturforskel mellem forbindelserne I og forbindelserne III bestâr i tetrazolylgruppen i de ^ ved fremgangsmâden ifolge opfindelsen fremstillede forbin-delser befinder sig i stilling 3, mens de i de kendte for-bindelser befinder sig i stilling 7, altsâ pâ benzenringen, hvor ogsâ en eventuelt substituent X har sin plads.
Det har vist sig at denne strukturforskel betinger on en ganske staerk virknmgsforskel mellem forbindelserne som det fremgâr af det nedenfor beskrevne forsog. Dette forsog udfortes med 8 uger garnie rotter af stammen Sprague-Dawley og med en vægt pâ 220-320 g. Der blev fremstillet rotte- antiserum indeholdende IgE antistof ved den af Mota (Life 35
Soi. 2, 917, 1963) angivne metode. Beskrevet i korthed blev dyrene sensitiveret ved intramuskulær injektion i hvert
DK 156725B
2 bagben af 1 mg ægalbumin i 1 ml fysiologisk saltoplosning, samtidig med intraperitoneal injektion af 1 ml suspension 10 . af 2x10 dræbte celler af Bordetella pertussis. Sérum md- samlet fra hvert af dyrene 12 dage efter sensitiveringen 5 blev forenet og frosset indtil brugen. Virkningen af test-stofferne blev belyst ved den passive kutane anafylakse-test (PCA) pâ rotter. Det homologe PCA-respons blev frem-kaldt pâ folgende mâde: fire 0,05 ml store prover sérum fortyndet fire gange med fysiologisk saltoplosning blev in-10 jiceret intradermalt i rottens barberede ryghud. Efter en latensperiode pâ 72 timer i faste blev rotten belastet ved intravenos injektion af 1 ml saltoplosning indeholdende 5 mg ægalbumin og 10 mg Evans-blât. Rotterne blev dræbt (blodning) 30 minutter efter antigenbelastningen, huden 15 blev flâet af og intensiteten af PCA-reaktionen bedomt ved mâling af den længste diameter af vablen, som var farvet med Evans-blât idet arealet blev mâlt i mm . De antisera som indeholdt IgE gav PCA-titere pâ 1:16.
Teststoffernes virkning blev bedomt ved den procent-20 vise inhibering af gennemsnitsstorrelsen af PCA-reaktionen hos fem dyr, eller den dosis der giver 50% inhibering, be-regnet grafisk ud fra relationen mellera dosis og inhibering.
Teststoffer suspenderet i 5%s gummi arabicum blev 25 indgivet oralt 5 minutter for antigenbelastningen. Det ind-givne rumfang fra 0,2 ml pr. 100 g legemsvægt.
Virkningen af teststofferne pâ den 72 timers PCA · hos rotter var som folger: 30 Tabel 1
Forb. Dosis, Antal PCA, Inhibering, mg/kg, rotter __2 % ·,? mro oralt
Kontrol — 5 190+10 35 A 10 5 44+12***,Δ 77 B 10 5 102+20** 46
DK 156725 B
3
** p<0,01, *** p<0,001 Signifikant forskel fra kontrollen Δ p<0,05 Signifikant forskel fra forbindelse B
Forbindelse A er 3-(1H-tetrazol-5-yl)-1-azaxanton 5 fremstillet ved fremgangsmâden ifolge opfindelsen og forbindelse A den fra modholdet kendte, nærmest muligt beslæg-tede forbindelse, nemlig 7-(1H-tetrazol-5-yl)-1-azaxanton. Disse resultater viser sâledes at forskydning af tetrazo-lylgruppen fra 7-stillingen til 3-stillingen giver forbed-10 ret antiallergisk virkning.
Pâ lignende mâde er der foretaget forsog med en række af de ved fremgangsmâden ifolge opfindelsen frem-stillede forbindelser, og i disse tilfælde er der tillige beregnet konfidensgraenser (vist i parenteser). Resultater-15 ne fremgâr af nedenstâende tabel 2, hvor ID^g er den dosis der behoves til 50% inhibering.
Tabel 2
Anti-PCA aktivitet af 3-(tetrazol-5-yl)-1-azaxantoner 20 r-rVV1 Γ TT η T /n-n i 2j- Forb. R R Rotte PCA, ID,-q, mg/kg, i.v.
24a H H 0,44 (0,35-0,57) 24b 7-Et H 0,11 (0,087-0,16) 24c 7-i-Pr H 0,0096 (0,0086-0,011) 24d 7-t-Bu H 0,047 (0,036-0,069) 30 24e 7,9-Me2 H 0,31 (0,056-0,54) 24f 6,7-benzo H 0,84 (0,58-1,67) 24g 7-i-Pr NH2 0,064 (0,0096-0,42) 35 Det ses at de fleste af de afprcvede forbindelser endog har bedre virkning end ovennævnte forbindelse A.
2 4
DK 156725 B
Substituenten eller substituenterne R kan befinde sig i hvilke som helst af stillingerne 6-, 7-, 8- og 9 i azaxantonringen.
2
Alkylgruppen R kan være en ligekædet, for- 5 grenet eller cyklisk alkylgrupe med 1-6 kulstofatomer og £x være metyl, ætyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, hexyl, cyklopentyl eller cyklo- hexyl. Alkylgrupper med 1-3 kulstofatomer foretrækkes.
2
Alkoxygruppen R med 1-4 kulstofatomer kan fx være metoxy, 10 ætoxy, propoxy, isopropoxy eller butoxy. Et halogenatom 2 R kan være klor, brom, jod eller fluor. En aminogruppe 2 R kan være en mono- eller disubstitueret aminogruppe med C^_2 alkyl og fx være metylamino, ætylamino, propylamino, isopropylamlno, dimetylamino, diætylamino eller dipropyl-15 amino.
Fremgangsmâden ifolge opfindelsen bestâr i omsæt-ning af en forbindelse med formlen II med hydrogenazid eller et sait deraf. Som eksempler pâ salte af hydrogenazid kan nævnes salte med alkalimetaller sâsom litiumazid, na-20 triumazid og kaliumazid; jordalkalimetaller sâsom magnium-azid, kalciumazid, bariumazid og strontiumazid; og andre uorganiske salte sâsom aluminiumazid, tinazid, zinkazid, eller titanazid samt med organiske baser son airmoniak og anilin. Saltet af hydrogenazid kan anvendes alene eller i kombina-25 tion med visse andre forbindelser. Fx kan et alkalimetal-azid, fx natriumazid, anvendes sammen med en Lewis-syre, fx aluminiumklorid, stanniklorid, zinkklorid eller titan-klorid, eller ammoniumklorid. Det er sandsynligt at alkali-metalsaltet af hydrogenazid i reaktionssystemet omdannes 30 til en anden azid svarende til kationen i den ledsagende forbindelse, nemlig aluminiumazid, tinazid, zinkazid, titanazid, ammoniumazid eller lignende og at dette andet azid derpâ reagerer med udgangsforbindelsen med formel II.
Blandt hydrogenazid, salte deraf og forskellige kombina-35 tioner af disse salte med de nævnte andre forbindelser er kombinationen af natriumazid med ammoniumklorid den mest onskelige.
DK 156725B
5
Almindeligvis gennemf0res reaktionen i et organisk oplosningsmiddel. Soin eksempler herpâ kan nævnes kulbrin-ter som tetrahydrofuran, dioxan, ætylæter og ætylenglykol-dimetylæter, acetonitril, dimetylformamid, formamid og dime-5 tylsulfoxyd. Temperatur, tid og ovrige betingelser for reaktionen er ikke kritiske, og det er som regel fordelag-tigt at udfore reaktionen ved fra stuetemperatur til 150°C i 1 time til 2 dage.
Nâr der anvendes et sait af hydrogenazid som sâdant, 10 vindes den onskede forbindelse I som et sait svarende til det anvendte hydrogenazidsalt, hvilket skyldes tetrazol-ringens surhed. Saltet kan ved behandling med en syre, fx en mineralsyre sâsom saltsyre eller svovlsyre, let omdan-nes til den onskede forbindelse med formel I med fri tetra-15 zolring. Omsætning af en hvilken som helst forbindelse I med en organisk amin, et alkalimetalhydroxyd, ammoniak eller andet reagens pâ kendt mâde, fx under opvarmning i et oplosningsmiddel, giver det tilsvarende sait af en forbindelse I. Som eksempler pâ sâdanne saltdannende reagenser 20 nævnes organiske aminer som ætanolamin, diætanolamin, dl-metylefedrin, 1-(3,5-dihydroxyfenyl)-L-isopropylaminoæta-nol, isoproterenol, dextrometorfan, hetrazan (diætylkarbama-zin), di- og triætylamin; alkalimetalhydroxyder som natri-umhydroxyd og kaliumhydroxyd, samt ammoniak.
25 Forbindelserne med formel I har som nævnt antial- lergisk virkning og er værdifulde som lægemidler til fore-byggelse og behandling af sâdanne allergisygdomme som allergisk astma, allergisk dermatitis og hofeber.
Forbindelser med formel I eller salte deraf kan 30 indgives oralt i sâdanne dosisformer som tabletter, kap- sler, pulvere og oplosninger, sædvanligvis i en daglig do-sissstorrelse pâ 1-500 mg til voksne mennesker. De kan ogsâ indgives ad andre veje, som injektionsblandinger, ae-rosolinhaleringsmidler og salver.
35 Forbindelsen med formel II kan fremstilles pâ fol- gendemâde.
DK 156725B
6
En forbindelse med formlen 5 2 hvor m og R har de ovenfor angivne betydninger, der kan fremstilles fx som beskrevet i J. Med. Chem. 20, 144 (1977), omsættes med vand i nærværelse af en base til frem-10 stilling af en forbindelse <*>„-+- i I 111 0 15 2 hvor m og R har de ovenfor angivne betydninger.
Som eksempler pâ den base der anvendes ved denne reaktion kan nævnes primære aminer sâsom ætylamin, n-pro-pylamin, n-butylamin, benzylamin og anilin; sekundære aminer, fx metylamin, diætylamin, dipropylamin, dibutylamin, 20 morfolin, piperidin og pyrrolidin; tertiære aminer, fx tri- ætylamin; heterocykliske baser, fx imidazol, 2-metylimida- zol og pyridin; ammoniakvand, ammoniumacetat, ammoniumkar- bonat, natriumkarbonat og natriumhydrogenkarbonat. De kan anvendes i en praktisk tait valgfri mængde, fra en kataly-25 tisk mængde til stort overskud.
I almindelighed gennemfores reaktionen i et vand-i* blandbart oplosningsmiddel. Som eksempler nævnes dimetyl- formamid, dimetylsulfoxyd, hexametylfosforsyretriamid, syrer som myresyre, eddikesyre, propionsyre og ætere sâsom 30 tetrahydrofuran og dioxan.
Temperatur, tiden og ovrige betingelser er ikke kri-tiske; som regel er det fordelagtigt at gennemfore reaktionen ved mellem stuetemperatur og 100°C, i nogle minut- ter til ca. 3 timer.
35
Den sâledes vundne forbindelse III oms.ættes yderli- gere med en forbindelse med formlen i
DK 156725 B
7
R3-CN V
hvor R3 er HC^c-, NH-CH2-, R4OCOCH2-f hvor R4 er en alkyl-gruppe med 1-3 kulstofatomer, eller XOC-CH2~, hvor X er 5 halogen, til at danne forbindelsen med formel II. Eksem- pler pâ forbindelser V hvori R3 er R4OCOCH2~ er metylcyano-acetat, ætylcyanoacetat og propylcyanoacetat.
3
Omsaetningen af forbindelserne III og IV, hvori R
4 er HC=C-, NC-CH2~ eller R OCOCH2-, kan ske ι nærværelse 10 eller fraværelse af en base. Som eksempler kan nævnes primære, sekundære og tertiære aminer, fx ætylamin, n-propyl-amin, n-butylamin, benzylamin og anilin, dimetylamin, di-ætylamin, dipropylamin, dibutylamin, morfolin, piperidin og pyrrolidin, triætylamin; og heterocykliske aminer, fx Ί5 imidazol, 2-metylimidazol og pyridin; uorganiske baser sâ-som vandig ammoniak, ammoniumacetat, ammoniumkarbonat, na-triumkarbonat og natriumhydrogenkarbonat. Baserne kan an-vendes i næsten valgfrie mængder fra katalytisk mængde til et stort overskud, 20 Som regel gennemfores denne reaktion i et organisk oplosningsmiddel. Som eksempler nævnes dimetylformamid, dimetylsulfoxyd, formamid, hexametylfosforsyreamid, tetra-hydrofuran og dioxan; metanol, aetanol, propanol og butanol; ætylacetat og metylpropionat, og acetone og metylætylketon.
25 Temperaturen, tiden og ovrige reaktionsbetingelser er ikke kritiske, ofte er det fordelagtigt at udfore reak-tionen ved mellem stuetemperatur og 180°C i fra nogle mi-nutter til ca. 24 timer.
Forbindelsen II kan ogsâ fremstilles ved omsætning 3 30 af en forbindelse III med en forbindelse IV hvori R er XOC-CH2~, dvs. cyanoacetylhalogenid, i nærværelse af et substitueret formamid. Det i denne reaktion anvendte cyanoacetylhalogenid er fx cyanoacetylklorid, cyanoacetylbro-mid, cyanoacetyljodid eller cyanoacetylfluorid. Det anvend-35 te substitueret formamid er fx et alkyl- eller arylsubsti-tueret formamid, sâsom N,N-dimetylformamid, N,N-diætylform-
DK 156725B
8 amid, Ν,Ν-dipropylformamid, N-metyl-N-ætylformamid, N-me-tyl-N-fenylformamid eller N,N-difenylformamid. Reaktionen kan gennemfores i nærværelse af et sâdant substitueret form-amid alene, dvs. under anvendelse af det soin reaktionsop-5 losningsmiddel, men reaktionen kan ogsâ gennemfores i en blanding af det substituerede formamid og et andet oplos-ningsmiddel som pâvirker reaktionen skadeligt. Oplosnings-midlet er fortrinsvis et organisk oplosningsmiddel, fx ben-zen, toluen, xylen, petroleumsæter; tetrahydrofuran, dioxan 10 ætylæter, ætylenglykoldimetylæter; kloroform, diklormetan, diklorætan, tetraklorætan; ætylacetat, metylacetat, butyl-acetat; acetonitril eller dimetylsulfoxyd. Cyanoacetylha-logenidet bruges sædvanligvis i en mængde pâ 1-10 molaekviva-lenter i forhold til udgangsforbindelsen med formel III.
15 Reaktionsbetingelserne er ikke kritiske; normalt udfores reaktionen ved 20-120°C i 30 minutter til ca. 2 dage. Maeng-den af substitueret formamid er ikke saerlig kritisk. Der bruges fortrinsvis 2 eller flere molækvivalenter i forhold til udgangsforbindelsen med formel III.
i 20 En forbindelse II, hvori R er hydroxyl kan ogsâ fremstilles ved at omsætte en forbindelse II, hvori R^ er en aminogruppe, med et alkalimetalsalt af salpetersyr-ling, fx natriumnitrit eller kaliumnitrit, i en vandig syre-oplosning af fx eddikesyre eller saltsyre.
25 Opfindelsen belyses nærmere i det folgende ved hjælp af nogle eksempler der beskriver fremstillingen af udgangs-forbindelser, og nogle eksempler der belyser fremgangsmâ*-den ifolge opfindelsen.
30 a. Udqangsmaterialer Referenceeksempel 1
En blanding af 2 ml morfolin, 3 ml dimetylfor'mamid og 10 ml vand opvarmedes til 60°C og under omroring tilsat- 35 tes i lobet af 5 minutter 1,71 g pulveriseret 4-oxo-4H-1-benzopyran-3-karbonitril. Blandingen holdtes ved den nævnte temperatur endnu 1 time hvorefter bundfaldet fra- 9
DK 156725 B
filtreredes, skylledes med vand, omkrystalliseredes fra eddikesyre og vaskedes med kloroform. Herved vândtes 1,3 g krystaller af 2-amino-4-oxo-4H-1-benzopyran-3-karboxalde-hyd med smp. 252-255°C (s0nderdeling).
5 NMR (DMSO-dg) ô: 10,19 (1H,s), 9,67 (ca. 1,5H,br.s), 8,11 (1H,dd,J=2,8Hz), 7,97-7,80(3H,m).
Beregnet for C^H^NO^: C 63,49 H 3,73 N 7,41
Fundet: C 63,59 H 3,44 N 7,45% Pâ samme mâde syntetiseredes folgende forbindelser, 10 hvor Omkr. stâr for oplosningsmidlet til omkrystallisa-tion.
Udgangsforbindelse Produkt Smp. (°C)/0mkr.
15 6-metyl-4-oxo-4H-l- 2-amino-6-metyl-4- 282-284 (s0nderd.} benzopyran-3-karbonitril oxo-4H-l-benzopyran- eddikesyre 3-karboxaldehyd 6-ætyl-4-oxo-4H-l- 2-amino-6-ætyl-4-oxo-246-249 (s0nderd. ) benzopyran-3-karbonitril 4H-l-benzopyran-3- acetone karboxaldehyd 20 6-klor-4-oxo-4H-l- 2-amino-6-klor-4- 308-310 (s0nderd. ) benzopyran-3-karbo- oxo-4H-l-benzopyran- eddikesyre nitril 3-karboxaldehyd β-metoxy-4-oxo-4H-1- 2-amino-6-metoxy-4- 251-254 (s0nderd.} benzopyran-3-karbo- oxo-4H-l-benzopyran- kloroform nitril 3-karboxaldehyd 25 30 35 10
DK 15672SB
Udgangsforbindelse Produkt Smp. (°C)/Omkr.
6,8-dimetyl-4-oxo-4H- 2-amino-6,8-dimetyl- 259-263 (s0nderd.) l-benzopyran-3-karbo- 4-oxo-4H-l-benzopy- eddikesyre nitril ran-3-karboxaldehyd 5 7-hydroxy-4-oxo-4H- 2-amino-7-hydroxy- 297-300 (s0nderd.) l-benzopyran-3- 4-oxo-4H-l-benzopy- eddikesyre karbonitril ran-3-karboxaldehyd 6-nitro-4-oxo-4H-l- 2-amino-6-nitro-4- 290-293 (s0nderd.) benzopyran-3-karbo- oxo-4H-l-benzopyran- myresyre nitril 3-karboxaldehyd 10 6-isopropyl-4-oxo-4H- 2-amino-6-isopropyl- 206-208 l-benzopyran-3-karbo- 4-oxo-4H-l-benzopy- eddikesyre nitril ran-3-karboxaldehyd 6-n-butyl-4-oxo-4H-l- 2-amino-6-n-butyl-4- 220-222 benzopyran-3-karbo- oxo-4H-l-benzopyran- eddikesyre ^ nitril 3-karboxaldehyd 8-metoxy-4-oxo-4H-l- 2-amino-8-metoxy-4- 235-238 benzopyran-3-karbo- oxo-4H-l-benzopyran- kloroform nitril 3-karboxaldehyd 3-cyano-benzo[f]- 2-amino-benzo[f]- 258-260 (s0nderd.
kromon kromon-3-karboxal- under skumning) 2 0 dehyd eddikesyre 6-dimetylamino-4-oxo- 2-amino-6-dimetyl- 276-280 (s0nderd. ) 4H-l-benzopyran-3- amino-4-oxo-4H-1- kloroform/metanol karbonitril benzopyran-3-karbox- aldehyd 6-t-butyl-4-oxo-4H- 2-amino-6-t-butyl- 240-242 25 1-benzopyran-3-karbo- 4-oxo-4H-l-benzopy- eddikesyre nitril ran-3-karboxaldehyd 6-isopropoxy-4-oxo- 2-amino-6-isoprop- 218-219 4H-l-benzopyran-3- oxy-4-oxo-4H-l-benzo-kloroform karbonitril pyran-3-karboxaldehyd 30
Referenceeksempel 2
En blanding af 217 mg 2-amino-6-ætyl-4-oxo-4H-l-benzopyran- 3-karboxaldehyd, 300 mg malononitril, 5 ml ætanol og 0,5 ml pipe-ridin omr0rtes under tilbagesvaling i 15 minutter og efter afk0-
OC
ling opsamledes det svagt opl0selige produkt ved filtrering og om-krystalliseredes fra dimetylformamid. Ved den ovennævnte procedure vandtes 160 mg 2-amino-7-ætyl-l-azaxanton-3-karbonitril som farve-10se nâle med smp. over 300°C.
DK 156725 B
11
Infrar0dt absorptionsspektrum (Nujol) cm”'1': 3325, 3125, 2225, 1660. Kernemagnetisk resonansspektrum (CFgCOOD) δ: 9,07 (1H, s), 8,16 (1H, d, J=2Hz), 7,88 (1H, dd), 7,63 (1H, d, J=9Hz), 2,92 (2H, kv., J=7Hz), 1,39 (3H, t, J=7Hz).
Beregnet for £ΐ5ΗιχΝ302: c 67,91 H 4,18 N 15,84 Fundet: C 67,75 H 4,01 N 16,00%.
F01gende forbindelser fremstilledes ved tilsvarende frem-gangsmâde.
^ Udgangsforbindelse Produkt Smp. (°C)/Omkr.
2-amino-4-oxo-4H-1- 2-amino-1-azaxan- >300 benzopyran-3-karbox- ton-3-karbonitril dimetylformamid aldehyd 15 2-amino-6-klor-4~oxo- 2-amino-7-klor-l- >300 4H-l-benzopyran-3- azaxanton-3-karbo- dimetylformamid karboxaldehyd nitril 2-amino-6-dimetyl- 2-amino-7-dimetyl- >300 amino-4-oxo-4H-1- amino-l-azaxanton- ætanol b en zopyran-3-karbox- 3-karbonitri1 aldehyd 2-amino-6-isopropy1-4- 7-isopropyl-2-ami- >300 oxo-4H-l-benzopyran-3- no-3-cyano-l-aza- dimetylformamid karboxaldehyd xanton 2-amino-6-mety1-4- 7-metyl-2-amino-3- >300 oxo“4H-l-benzopyran- cyano-l-azaxanton dimetylformamid 25 3-karboxaldehyd 2- amino-8-metoxy-4- 9-metoxy-2-amino- >300 oxo-4H-l-benzopyran- 3-cyano-l-azaxanton dimetylformamid 3- karboxaldehyd 2-amino-benzo[f]- 2-amino-3-cyano- >300 kromon-3-karbox- benzo[h]-1-aza- dimetylformamid aldehyd xanton
Referenceeksempel 3 I 40 ml dimetylformamid opl0stes 1,82 g 2-amino-6-ætyl-4-35 oxo-4H-l-benzopyran-3-karboxaldehyd, hvorefter der tilsattes 3,5 g cyanoacetylklorid. Blandingen omsattes ved 60°C i 3 timer under konstant omr0ring. Derpa afdestilleredes opl0sningsmidlet under nedsat trvk οσ remanensen kromatoaraferedes oâ silikaael. Det <ân-
DK 156725B
12 fra acetonitril. Ved den ovennævnte procedure vandtes 1,03 g 7-ætyl-3-cyano-1-azaxanton med smp. 183-185°C.
F0lgende forbindelser fremstilledes pâ sairtme mâde.
5 ——-
Udgangsforbindelse Produkt Smp. ( C)/Omkr.
2- amino-6-metyl-4- 7-metyl-3-cyano- 240-242 oxo-4H-l-benzopyran- 1-azaxanton ætanol 3- karboxaldehyd 10 2-amino-4-oxo-4H-l- 3-cyano-l-aza- 220-226 benzopyran-3-karbox- xanton ætanol aldehyd 2- amino-6-isopropyl- 7-isopropyl-3-cyano- 203-205 4- oxo-4H-l-benzopyran- 1-azaxanton ætanol 3- karboxaldehyd 15 2-amino-6-klor-4-oxo- 7-klor-3-cyano-l- 286-288 4H-l-benzopyran-3- azaxanton dlmetylformamid karboxaldehyd 2- amino-6,8-dimetyl- 7,9-dimetyl-3-cyano- 254-257 4- oxo-4H-l-benzopyran- 1-azaxanton acetonitril 3- karboxaldehyd 2- amino-6-t-butyl- 7-t-3-cyano-l- 247-249 4- oxo-4H-l-benzopyran- azaxanton acetonitril 3- karboxaldehyd __
Referenceeksempel 4 25 -----------------------
Til 70 ml dimetylformamid sattes 2,2 g 2-amino-4-oxo-4H-l-benzopyran-3-karboxaldehyd hvorefter der tilsattes 2,5 g cyanoace-tylen. Blandingen opvarmedes under omr0ring ved 140°C i 15 timer og opl0sningsmidlet afdestilleredes derpâ under nedsat tryk. Rema-30 nensen kromatograferedes pâ silikagel og elueredes med kloroform og omkrystalliseredes fra acetonitril hvorved der vandtes 0,83 g 3-cyano-1-azaxanton som krystaller med smp. 22Q-226°C. Kernemagnetisk resonansspektrum (DMSO-dgl 7,4^8,4 (4H, m), 9,10 (1H, d, J=2Hz), 9,30 (1H, d, J=2Hz).
35 Beregnet for C13H6N202: C 70,27 H 2,72 N 12,61 Fundet: C 70,12 H 2,55 N 12,50%.
F0lgende forbindelser fremstilledes pâ tilsvarende mâde.
DK 156725 B
13 üdgangsforbindelse Produkt Smp. (°C)/Omkr.
2-amino-6-metyl-4-oxo- 7-metyl-3-cyano- 240-242 4 H-1-benzopyran-3- l-azaxanton ætylacetat karboxaldehyd 5 2-amino-6-ætyl-4-oxo- 7-ætyl-3-cyano-l- 183-185 4H-l-benzopyran-3- azaxanton acetonitril karboxaldehyd 2- amino-6-isopropyl- 7-isopropyl-3-cyano- 203-205 4-oxo-4H-l-benzopyran- l-azaxanton ætanol 3- karboxaldehyd 10 2- amino-6-isopropoxy-4- 7-isopropoxy-3-cyano-259-261 oxo-4H-l-benzopyran- l-azaxanton kloroform/acetonitril 3- karboxaldehyd 2-amino-6,8-dimety1-4- 7,9-dimetyl-3-cyano- 254-257 oxo-4H-l-benzopyran- l-azaxanton acetonitril ^ 3-karboxaldehyd 2- amino-8-metoxy-4- 9-metoxy-3-cyano- >300 oxo-4H-l-benzopyran- l-azaxanton dimetylformamid 3- karboxaldehyd 2- amino-benzo[f]- 3-cyano-benzo[h]-l- 234-239 kromon-3-karboxyaldehyd azaxanton kloroform/ætanol 20
Referenceeksempel 5
Til en opl0sning af 0,5 g 7-isopropyl-2-amino-3-cyano-l-aza-xanton i 80 ml eddikesyre sattes gradvist 1,0 g natriumnitrit ved 70°C. Efter en période pâ 1 time tilsattes 3 ml vand og blandingen opvarmedes til 70 C i yderligere 1 time. Opl0sningsmidlet afde-stilleredes under nedsat tryk og derpâ sattes der vand til remanen-sen. Det gule bundfald opsamledes ved filtrering, skylledes med vand og omkrystalliseredes fra ætanol hvorved der vandtes 7-isopro-pyl-2-hydroxy-3-cyano-l-azaxanton som gule krystaller med smp.
30 over 300°C.
Beregnet for c^gHi2N2°3: c 68,56 H 4,32 N 10,00 Pundet: C 68,28 H 4,34 N 9,70%.
Referenceeksempel 6 35 -------------------
En blanding af 1,73 g 2-amino-6-metoxy-4-oxo-4H-l-benzopyran- 3- karboxaldehyd, 3,2 ml ætylcyanoacetat, 80 ml ætanol og 1,6 ml m'neridin koo-hes nnde-r ii 1 haaesva li ησ under keneiani mnrrtrinrT i
DK 156725 B
14 piperidin og derpâ kogtes blandingen i yderligere 3 tinter under tilbagesvaling. Efter afk01ing opsamledes bundfaldet ved filtre-ring og oïnkrystalliseredes fra kloroform/ætanol (2:1).
Ved den ovenfor beskrevne procedure vandtes 1,91 g ætyl-2-amino-7-metoxy-l-azaxanton-3~karboxylat som farvel0se nâle med smp. 286-288°C.
Pâ den anden side koncentreredes den ved filtreringen vundne môdervæske. Det resulterende bundfald opsamledes ved filtrering og opl0stes i kloroform. Kloroformopl0sningen kromatograferedes " pâ 14 g silikagel og eluering gennemf0rtes med kloroform/acetone/ myresyre i forholdet 9:1:0,1 og derpâ med kloroform/acetone/myre-syre i forholdet 2:1:0,1. Begge eluater forenedes og koncentreredes derpâ. Remanensen omkrystalliseredes fra dimetylformamid/aetanol hvorved der vandtes 75 mg 2-hydroxy-7-metoxy-l-azaxanton-3-karbo- nitril som et hvidt fast stof med smp. >300°C.
15 IR (Nujol) cm : 2250 (CN), 1680, 1640.
NMR (CF3C02D) δ: 9,20 (1H, s), 7,90 (1H), 7,75 (2H, s), 4,10 (3H, s).
Beregnet for C14HgN204,1/4H20: C 61,76 H 3,14 N 10,29 Fundet: C 61,76 H 2,90 N 10,31%.
20 B. Fremganqsmâde ifolge opfindelsen Eksempel 1 I 50 ml dimetylformamid opl0stes 0,50 g 7-isopropyl-3-cyano- 1-azaxanton hvorefter der tilsattes 0,362 g natriumazid og 0,282 g 25 ammoniumklorid. Reaktionen gennemf0rtes ved 120°C i 2 timer under konstant omr0ring. Derpâ destilleredes reaktionsblandingen til fjernelse af opl0sningsmidlet og der sattes 5 ml vand til remanensen hvorefter der tilsattes 5 ml af en 5%s natriumnitritopl0sning. Blandingen blev gjort sur med 10%s HCl og det resulterende bundfald 20 opsamledes, skylledes med vand og omkrystalliseredes fra dimetylformamid. Ved den ovennævnte procedure vandtes 0,31 g krystaller af 7-isopropyl-3-(lH-tetrazol-5-yl)-l-azaxanton med smp. 275-277°C (s0nderdeling under skumdannelse).
NMR (DMSO-dg). δ: 1,30 (6H, d, J=7), 3,00 (1H, kvintet, J=7), 7,70 35 (1H, d, J=8), 7,90 (1H, dd, .1-,=2, J2 = 8), 8,03 (1H, d, J=2), 9,15 (1H, d, J=2), 9,38 (1H, d, J=2).
Pâ samme mâde som beskrevet ovenfor syntetiseredes f01gende forbindelser.
DK 156725B
15 3-(1H-tetrazol-5-yl)-1-azaxanton, smp. >300°C; 7-ætyl-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. 262-265°C (s0nder-deling under skumdannelse); 7-isopropyl-2-amino-3-(lH-tetrazol-5-yl)-l-azaxanton, smp. >300°C; 7-isopropyl-2-hydroxy-3-(lH-tetrazol-5-yl)-1-azaxanton, smp.
>300°Cj 7,9-dimety1-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. 294-298°C; 7-t-butyl-3-(lH-tetrazol-5-yl)-l-azaxanton, smp. 273-275°C (s0nderdeling); 7-isopropoxy-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. 271-272°C (s0nderdeling); 7- klor-3-(1H-tetrazol-5-yl)-1-azaxanton, smp. >30Q°C; 3-(lH-tetrazol-5-yl)-benzo[h]-1-azaxanton, smp. 291-293°C (s0nder-deling); 9-metoxy-3-(IH-tetrazol-5-yl)-1-azaxanton, smp. >300°C.
15
Eksempel 2 I 150 ml ætanol suspenderedes 2,0 g 6-klor-2-aminokromon-3-karboxaldehyd efterfulgt af tilsætning af 1,3 g malononitril og 20 5 ml piperidin. Blandingen omsattes under tilbagesvaling i 2 timer.
Reaktionsblandingen destilleredes derpâ under nedsat tryk hvorved fraktioner kogende ved og under 100°C afdestilleredes. Til remanen-sen sattes 50 ml dimetylformamid hvorefter der tilsattes 0,5 g natriumazid og 0,4 g ammoniumklorid. Reaktionsblandingen gennem-25 f0rtes under omr0ring ved 140°C i 2 timer og ved slutningen af denne période afdestilleredes opl0sningsmidlet under nedsat tryk. Remanensen fortyndedes med vand, behandledes med 6 ml 10%s natri-umnitrit og syrnedes med 10%s saltsyre. Det resulterende bundfald opsamledes ved filtrering, skylledes med vand og omkrystalliseredes 30 fra dimetylformamid. Ved den ovennævnte procedure vandtes krystal-ler af 7-klor-2-amino-3-(lH-tetrazol-5-yl)-1-azaxanton med smp. >300°C.
Pâ samme mâde som beskrevet ovenfor syntetiseredes f0lgende forbindelser.
33 7-nitro-2-amino-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. >3Ot)°C; 9-metoxy-2-aminô-3-(lH-tetrazol-5-ÿl)-1-azaxanton, smp. >300°C; 8- hydroxy-2-amino-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. >300°C; r» λ PUT O _ ->tv* «5 v\ v\— l 1 XJ_ 4— λ4- k*^ ^ — T _ n r»n S Ο · 16
DK 156725 B
7-dimetylamino-2-amino--3-(lH-tetrazol-5-yl)-1-azaxanton, smp.
>300°C og 7,9-dimetyl-2-amino-3-(lH-tetrazol-5-yl)-1-azaxanton, smp. >300°C.
Eksempel 3 5 __________
Til en opl0sning af 0,163 g 7-isopropyl-2-amino-3-(lH-tetra-zol-5-yl)-1-azaxanton i 20 ml metanol sattes 0,1 g diætanolamin hvorpâ der opvarmedes til 60°C i 10 minutter.
Efter afk01ing opsamledes de udskilte krystaller og disse 1 0 omkrystalliseredes fra metanol hvorved der vandtes 7-isopropyl- 2-amino-3-(lH-tetrazol-5-yl)-l-azaxanton-diætanolaminsalt som far-vel0se nâle med smp. >300°C.
Pâ samme mâde som beskrevet ovenfor syntetiseredes forbindel-sen 7-isopropyl-3-(lH-tetrazol-5-yl)-1-azaxanton-diætanolaminsalt ^ med smp. 149-151°C.
20 25 30 35
Claims (2)
1. Analogifremgangsmâde til fremstilling af 3-(te-trazol-5-yl)-1-azaxantoner med den almene formel 5 , (R2 ) -J I | ? I 0 ^N-N H 1 2 10 hvor R er hydrogen, amino eller hydroxyl, og R er alkyl, C.j_4alkoxy, halogen, nitro, karboxyl, hydroxyl, butadienylen {-CH=CH-CH=CH-) som danner en benzenring med et hvilket som helst af nabokulstofatomerne, eller en aminogruppe som kan være usubstitueret eller substi- 15 tueret med 1-2, C.j ^alkylgrupper, og m er 0, 1 eller 2, eller fysiologisk acceptable salte deraf, kende- t e g n e t ved at man omsætter en forbindelse med form- len 1 (R )m-f II I \ 11 20 m J CN O 1 2 hvor R , R og m har de ovenfor angivne betydninger, med hydrogenazid eller et sait deraf, hvorpâ man om onsket omdanner den vundne forbindelse til et fysiologisk ac-25 ceptabelt sait deraf.
2. Fremgangsmâde ifolge krav 1, kendeteg- n e t ved at man freinstiller forbindelsen 3-(1H-tetra-zol-5-yl)-1-azaxanton. 30 35
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11581777 | 1977-09-26 | ||
JP52115817A JPS5825677B2 (ja) | 1977-09-26 | 1977-09-26 | 3−テトラゾ−ル−1−アザキサントン誘導体およびその製造法 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK418678A DK418678A (da) | 1979-03-27 |
DK156725B true DK156725B (da) | 1989-09-25 |
DK156725C DK156725C (da) | 1990-03-05 |
Family
ID=14671828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK418678A DK156725C (da) | 1977-09-26 | 1978-09-21 | Analogifremgangsmaade til fremstilling af 3-(tetrazol-5-yl)-1-azaxantoner |
Country Status (20)
Country | Link |
---|---|
US (1) | US4267332A (da) |
JP (1) | JPS5825677B2 (da) |
AT (1) | AT360988B (da) |
AU (1) | AU522242B2 (da) |
BE (1) | BE870736A (da) |
CA (1) | CA1090344A (da) |
CH (1) | CH638525A5 (da) |
DE (1) | DE2841644A1 (da) |
DK (1) | DK156725C (da) |
ES (1) | ES473680A1 (da) |
FR (1) | FR2404011A1 (da) |
GB (1) | GB2004551B (da) |
GR (1) | GR64802B (da) |
HU (1) | HU178360B (da) |
IT (1) | IT1101604B (da) |
NL (1) | NL188579C (da) |
NO (1) | NO149964C (da) |
SE (1) | SE434748B (da) |
SU (1) | SU858570A3 (da) |
ZA (1) | ZA785054B (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61172880A (ja) * | 1985-01-28 | 1986-08-04 | Takeda Chem Ind Ltd | 2−アミノ−5−オキソ−5H−〔1〕ベンゾピラノ〔2,3−b〕ピリジン−3−カルボン酸誘導体およびその製造法 |
JPS61215393A (ja) * | 1985-03-20 | 1986-09-25 | Takeda Chem Ind Ltd | 2−アミノ−5−オキソ−5H−〔1〕ベンゾピラノ〔2,3−b〕ピリジン−3−カルボン酸誘導体およびその製造法 |
US5831117A (en) | 1995-01-20 | 1998-11-03 | G. D. Searle & Co. | Method of preparing retroviral protease inhibitor intermediates |
JPH08325248A (ja) * | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法 |
KR980008226A (ko) * | 1996-07-05 | 1998-04-30 | 다케다 쿠니오 | 시각기능장애의 예방 및 치료제 |
US7268454B2 (en) * | 2003-01-17 | 2007-09-11 | Magnetic Torque International, Ltd. | Power generating systems |
US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2521980A1 (de) * | 1974-05-28 | 1975-12-18 | Yoshitomi Pharmaceutical | 1h-tetrazol-derivate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1403487A (en) * | 1972-07-21 | 1975-08-28 | Yoshitomi Pharmaceutical | Heterocyclic substituted alkanoic acids and derivatives |
NL7403583A (da) * | 1973-03-19 | 1974-09-23 | ||
JPS576433B2 (da) * | 1973-06-26 | 1982-02-04 |
-
1977
- 1977-09-26 JP JP52115817A patent/JPS5825677B2/ja not_active Expired
-
1978
- 1978-09-01 AU AU39488/78A patent/AU522242B2/en not_active Expired
- 1978-09-01 GR GR57139A patent/GR64802B/el unknown
- 1978-09-06 ZA ZA00785054A patent/ZA785054B/xx unknown
- 1978-09-18 US US06/942,925 patent/US4267332A/en not_active Expired - Lifetime
- 1978-09-19 GB GB7837321A patent/GB2004551B/en not_active Expired
- 1978-09-19 SE SE7809833A patent/SE434748B/sv not_active IP Right Cessation
- 1978-09-21 DK DK418678A patent/DK156725C/da not_active IP Right Cessation
- 1978-09-22 AT AT685478A patent/AT360988B/de not_active IP Right Cessation
- 1978-09-22 CA CA311,947A patent/CA1090344A/en not_active Expired
- 1978-09-22 HU HU78TA1495A patent/HU178360B/hu not_active IP Right Cessation
- 1978-09-22 IT IT27984/78A patent/IT1101604B/it active
- 1978-09-25 DE DE19782841644 patent/DE2841644A1/de active Granted
- 1978-09-25 SU SU782668856A patent/SU858570A3/ru active
- 1978-09-25 BE BE190684A patent/BE870736A/xx not_active IP Right Cessation
- 1978-09-25 FR FR7827423A patent/FR2404011A1/fr active Granted
- 1978-09-25 NO NO783233A patent/NO149964C/no unknown
- 1978-09-26 ES ES473680A patent/ES473680A1/es not_active Expired
- 1978-09-26 CH CH1003678A patent/CH638525A5/de not_active IP Right Cessation
- 1978-09-26 NL NLAANVRAGE7809741,A patent/NL188579C/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2521980A1 (de) * | 1974-05-28 | 1975-12-18 | Yoshitomi Pharmaceutical | 1h-tetrazol-derivate |
Also Published As
Publication number | Publication date |
---|---|
CA1090344A (en) | 1980-11-25 |
FR2404011A1 (fr) | 1979-04-20 |
BE870736A (fr) | 1979-03-26 |
SE7809833L (sv) | 1979-03-27 |
NO149964B (no) | 1984-04-16 |
JPS5825677B2 (ja) | 1983-05-28 |
CH638525A5 (de) | 1983-09-30 |
SE434748B (sv) | 1984-08-13 |
NL7809741A (nl) | 1979-03-28 |
US4267332A (en) | 1981-05-12 |
AT360988B (de) | 1981-02-10 |
DE2841644A1 (de) | 1979-04-05 |
SU858570A3 (ru) | 1981-08-23 |
AU522242B2 (en) | 1982-05-27 |
DK418678A (da) | 1979-03-27 |
HU178360B (en) | 1982-04-28 |
IT1101604B (it) | 1985-10-07 |
ES473680A1 (es) | 1979-04-16 |
DK156725C (da) | 1990-03-05 |
IT7827984A0 (it) | 1978-09-22 |
ZA785054B (en) | 1979-08-29 |
ATA685478A (de) | 1980-07-15 |
FR2404011B1 (da) | 1981-08-14 |
GB2004551B (en) | 1982-03-10 |
NO783233L (no) | 1979-03-27 |
AU3948878A (en) | 1980-03-06 |
JPS5448798A (en) | 1979-04-17 |
NL188579B (nl) | 1992-03-02 |
GB2004551A (en) | 1979-04-04 |
NO149964C (no) | 1984-07-25 |
GR64802B (en) | 1980-06-02 |
DE2841644C2 (da) | 1989-09-21 |
NL188579C (nl) | 1992-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS241391A3 (en) | Process for preparing biphenylcarbonitriles | |
EP0269378A1 (en) | Quinazolinone derivative and processes for preparing the same | |
Invidiata et al. | 1, 2, 4‐Triazoles. Improved synthesis of 5‐substituted 4‐amino‐3‐mer‐cato‐(4H)‐1, 2, 4‐triazoles and a facile route to 3, 6‐disubstituted 1, 2, 4‐triazolo [3, 4‐b][1, 3, 4] thiadiazoles | |
JPS62234069A (ja) | 2―ピラゾリン―5―オン類の製造法 | |
Cromwell et al. | γ-Keto-and γ-Hydroxy-γ-phenylbutyramides. Synthesis, Absorption Spectra and Structure Studies | |
Garratt et al. | One-carbon compounds as synthetic intermediates. The synthesis of hydropyrimidines and hydroquinazolines by sequential nucleophilic addition to diphenyl cyanocarbonimidate with concomitant cyclization | |
DK156725B (da) | Analogifremgangsmaade til fremstilling af 3-(tetrazol-5-yl)-1-azaxantoner | |
JPS633861B2 (da) | ||
JPS5817186B2 (ja) | 新規芳香族カルボン酸誘導体の製造方法 | |
US3461131A (en) | Process for preparing 2-substituted cycloheptimidazole derivatives | |
JPS6136754B2 (da) | ||
PL133507B1 (en) | Method of obtaining cymethydine | |
SU1147251A3 (ru) | Способ получени производных бензоилфенилпиперидина | |
US3505332A (en) | Certain 5-phenyl-2,4,7-triaminopyrido(2,3-d)pyrimidines | |
US3450709A (en) | Process for the preparation of ring-substituted 2-aminoimidazoles | |
US3287459A (en) | Carbostyrils, coumarines and thiocoumarines | |
GB1596376A (en) | 4,5-disubstituted imidazole-2-thiones processes for their preparation and their use as intermediates | |
US4423219A (en) | Production of purine derivatives and intermediates therefor | |
US4599428A (en) | Process for the preparation of 5(6)-thio substituted benzimidazoles | |
US4473697A (en) | Production of thiocyanato benzimidazoles | |
Takahashi et al. | Amidrazones and related compounds. V. The formation of pyrazole, 1H-1, 2, 4-triazepine, and 4H, 11H-[1, 5] diazocino-[2, 3-e: 6, 7-e'] di [1H-1, 2, 4] triazepine derivatives. | |
Spicer et al. | Synthesis of 6-phenyl-2, 3, 5, 6-tetrahydroimidazo [2, 1-b] thiazole | |
US4559401A (en) | Process for preparing chromophore-substituted vinyl-halomethyl-s-triazines | |
KR810001251B1 (ko) | 3-(테트라졸-5-일)-1-아자크산톤 유도체의 제조방법 | |
US3746701A (en) | Method for the production of benzodiazepine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |